Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

Inclusion Criteria: * Clinical diagnosis of transitional cell carcinoma of the urothelium that is locally advanced or metastatic (i.e. patients cannot be candidates for local/regional control of disease). * Relapse or progression within 12.5 months of prior cisplatin or carboplatin containing chemotherapy regimen. * Adequate performance status (Karnofsky greater or equal to 80). Exclusion Criteria: * Receipt of more than 1 prior chemotherapy regimen in any setting. * Prior discontinuation of platinum due solely to toxicity. * Current neuropathy greater or equal to CTC grade 2. * Prior radiation to greater or equal to 30% of bone marrow. * Inadequate hematologic function: ANC \<1,500 cells/mm3, Platelet\<100,000 cells/mm3. * Inadequate hepatic function: total bilirubin \> 1.5 times ULN, ALT/AST \> 2.5 times ULN or \> 5 times ULN in case of liver metastasis. * Inadequate renal function: creatinine clearance \<20 ml/min. * Prior allergy to any vinca-alkaloid.